Latest news

ABAC AbYlink Acteon afabicin (Debio 1450) afabicin (Debio 1450) ABSSSI afabicin (Debio 1450) Bone & joint infections altis labs Antibody Drug Conjufates Aspen Award BC Platforms Biocartis Campus après-demain CARB-X Carbonex CDiff Challenge Debiopharm-Inartis Clinical Trials Coorpacademy CPP cyclosporin A Debio 0123 Debio 0228 Debio 025 Debio 0432 Debio 0507 Debio 0513 Debio 0517 Debio 0614 (istaroxime) Debio 0615 Debio 0617 Debio 0719 Debio 0824 Debio 0826 Debio 0827 Debio 0928 Debio 0929 Debio 0930 Debio 0931 Debio 0932 NSCLS Debio 0932 RCC Debio 1036 Debio 1124 Debio 1124 SCLC Debio 1141 Debio 1142 Debio 1143 Debio 1143 Head & neck cancer Debio 1143 NSCLC Debio 1143 Ovarian cancer Debio 1143 selected solid tumors Debio 1143 with pembrolizumab Debio 1144 Debio 1347 Debio 1348 Debio 1449 Debio 1453 Debio 1454 Debio 1454M Debio 1454S Debio 1460 Debio 1561 Debio 1562 Debio 4126 Debio 8206 SC Debio 8609 Sanvar Debio 9902 - ZT-1 Debiopharm Academy Debiopharm Chair in Family Philanthropy Debiopharm Life Sciences Award Debiovision Degraducer Dexa Medica Diagnoplex EPFL EPI-hNE4 FibroTrap Fosanis fuze Galiena Capital genepoc genialis Groupe Bertrand H3 Pharma Haut-Lac HES-SO Huperzine-A IDEAL Iktos Immunexpress InnoCentive JCA-Mauvernay Award Kaiku Health KeyLemon little green house MedaSystems Mekonos Moapar Multilink Muscular Dystrophy naratuximab emtansine (Debio 1562) NeoVacs Novadiscovery nucleai Oncolifestyle Oncology Chair oncomfort Oxaliplatin paper.li PLGA Prix Debiopharm/Valais revogene Skiioo Spinomix Strategikon Swiss Biotech Association Téléthon Tremelimumab Triptorelin VeriSIM Life VivoSense Wazoku WhiteLab Genomics xevinapant YonaLink

April 23, 2015

Debiopharm International SA initiates clinical phase II study evaluating Debio 1450 in Staphylococcal skin infections

January 8, 2015

FDA Grants Fast Track designation to Debiopharm Group’s antibiotic Debio 1450

October 7, 2014

Debiopharm Group™ Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450, its Potent Anti-staphylococcal Agent

September 4, 2014

Debiopharm Group™’s innovative antibiotic Debio 1450 – developed from its proprietary plateform Fabiotics – Receives Qualified Infectious Disease Product (QIDP)…

June 26, 2014

Debiopharm Group™ and Nobelex Biotech start two collaborations on development of new antibiotics against N. gonorrhoeae and enteric species

June 19, 2014

Debiopharm Group™ Announces Initiation of a Phase I Study of Debio 1450, an IV/oral Potent Antibiotic Active Against Staphylococcal Infections

February 14, 2014

Debiopharm Group™ to Acquire Affinium’s Antibiotic Clinical Assets and Platform to Identify and Develop Targeted Antibiotics